Credit Suisse Raises Eli Lilly Price Target
Here are three takeaways on Credit Suiss's price target increase of Eli Lilly and Co (NYSE: LLY).
"1. We raise our target price to $65 (from $61).
2. Raising TP Following 3Q 2014, Remain Neutral While Watching Commercial Execution
3. We maintain our Neutral rating on the stock given the stock’s current valuation and look for successful commercial execution of new product launches, most notably Trulicity (dulaglutide)."
Shares of Eli lilly were up fractionally on average volume at $66.48.
Benzinga Color is embargoed from Benzinga Pro. The content above is delayed by 1.5 hours.
To get it live, subscribe to Benzinga Pro.
Latest Ratings for LLY
|Dec 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
|Nov 2016||BMO Capital||Downgrades||Outperform||Market Perform|
|Nov 2016||Atlantic Equities||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.